Regenxbio IncNASDAQ:RGNX
- LAST PRICE12.1000
- TODAY'S CHANGE (%)-0.3100 (-2.4980%)
- Bid / Lots12.0800/ 1
- Ask / Lots12.1300/ 2
- Open / Previous Close12.3300 / 12.4100
- Day Range
- 52 Week Range
- Volume63,252
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | RGNX |
|---|---|---|
| 09:32 ET | 13742 | 12.3 |
| 09:34 ET | 11678 | 12 |
| 09:36 ET | 14171 | 12.1 |
| 09:38 ET | 2013 | 12.205 |
| 09:41 ET | 250 | 12.135 |
| 09:43 ET | 700 | 12.25 |
| 09:45 ET | 100 | 12.22 |
| 09:48 ET | 976 | 12.225 |
| 09:50 ET | 1600 | 12.215 |
| 09:52 ET | 727 | 12.2 |
| 09:54 ET | 200 | 12.24 |
| 09:56 ET | 100 | 12.23 |
| 09:57 ET | 1648 | 12.235 |
| 09:59 ET | 400 | 12.32 |
| 10:01 ET | 300 | 12.305 |
| 10:03 ET | 200 | 12.305 |
| 10:06 ET | 1745 | 12.09 |
| 10:08 ET | 673 | 12.09 |
| 10:10 ET | 220 | 12.1 |
Jun 12, 2024
DJ Regenxbio Shifts CEO to Chairman, COO to Chief Executive, from 7:26AM ET on Wednesday Jun 12, 2024 by Dow Jones
7:26AM ET on Wednesday Jun 12, 2024 by Dow JonesREGENXBIO Announces Leadership Transition, from 7:05AM ET on Wednesday Jun 12, 2024 by Dow Jones
7:05AM ET on Wednesday Jun 12, 2024 by Dow JonesPress Release: REGENXBIO Announces Leadership Transition, from 7:05AM ET on Wednesday Jun 12, 2024 by Dow Jones
7:05AM ET on Wednesday Jun 12, 2024 by Dow Jones
Jun 7, 2024
DJ REGENXBIO Initiated at Buy by Goldman Sachs, from 7:38AM ET on Friday Jun 07, 2024 by Dow Jones
7:38AM ET on Friday Jun 07, 2024 by Dow Jones
Jun 5, 2024
REGENXBIO to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference, from 7:05AM ET on Wednesday Jun 05, 2024 by Dow Jones
7:05AM ET on Wednesday Jun 05, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Regenxbio Inc | 611.3M | -2.1x | --- |
Zymeworks Inc | 639.2M | -5.1x | --- |
Y-mAbs Therapeutics Inc | 522.6M | -24.1x | --- |
Urogen Pharma Ltd | 693.7M | -5.5x | --- |
SAGE Therapeutics Inc | 722.2M | -1.4x | --- |
Alector Inc | 451.1M | -3.4x | --- |
Company Information
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. The Company is focused on its internal development pipeline in three areas: retinal, neuromuscular and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202 and RGX-121. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.
Contact Information
- Headquarters
- 9804 Medical Center DriveROCKVILLE, MD, United States 20850
- Phone
- 240-552-8181
- Fax
- 302-655-5049
Executives
- Director
- Allan Fox
- Chairman of the Board
- Kenneth Mills
- Chief Financial Officer, Executive Vice President
- Vittal Vasista
- President, Chief Executive Officer, Director
- Curran Simpson
- Executive Vice President, Chief Scientific Officer
- Olivier Danos
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $611.3M |
|---|---|
Revenue (TTM) | $86.7M |
Shares Outstanding | 49.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.28 |
EPS | $-5.88 |
Book Value | $7.08 |
P/E Ratio | -2.1x |
Price/Sales (TTM) | 7.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -306.52% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
